48 results about "Pancreatic fibrosis" patented technology

The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and/or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and/or treat inflammatory and/or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and/or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.

Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1/DR4 and TRAIL-R2/DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1/DR4 and/or TRAIL-R2/DR5 agonists.

The invention relates to the fields of organic synthesis and medicinal chemistry and in particular relates to an O-(tetrahydropyrrole) ethyl derivatives of cleistanone, a preparation method of the O-(tetrahydropyrrole) ethyl derivative of cleistanone as well as application of the O-(tetrahydropyrrole) ethyl derivative of cleistanone in preparation of medicines for preventing or treating pancreatic fibrosis. A novel O-(tetrahydropyrrole) ethyl derivative of the cleistanone is synthesized, and the invention also discloses a preparation method of the O-(tetrahydropyrrole) ethyl derivative. The pharmacology experiment proves that the O-(tetrahydropyrrole) ethyl derivative of the cleistanone has an effect of preventing or treating the pancreatic fibrosis and has the value of developing the medicine for preventing or treating the pancreatic fibrosis.

This invention provides methods of inhibiting the onset or progression of a fibrotic disease (or pre-fibrotic pathology) in a mammal. The method involves administering oen or more peptides (e.g., class A amphipathic helical peptides, G* peptides, etc.) as described herein to a mammal in need thereof, in an amount effective to inhibit the onset and/or progression of the fibrotic disease (or pre-fibrotic condition) in the mammal. In certain embodiments the fibrotic disease is selected from the group consisting of retroperitoneal fibrosis (RPF), hepatic fibrosis and/or chirrhosis, renal fibrosis, and pancreatic fibrosis

The invention relates to the medical use of caterpillar fungus and provides application of caterpillar fungus to preparation of the medicine for preventing and/or treating pancreatic fibrosis. The medicine comprises caterpillar fungus used as an active component and one or more medical auxiliary materials; the caterpillar fungus is selected from natural caterpillar fungus, caterpillar fungus fermentation mycelia and an extract of natural caterpillar fungus and caterpillar fungus fermentation mycelia; the extract is selected from one or combination of a water extract, an alcohol extract, an ester extract, an ether extract and a chloroform extract. Through experiments, the influence of caterpillar fungus on rat pancreatic fibrosis is observed; the experiment shows that the caterpillar fungus has an effect of resisting pancreatic fibrosis; therefore, the caterpillar fungus can be used as the active component for preparing the medicine for resisting pancreatic fibrosis and is high in social benefit and research value.

The present invention provides an application of 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea in preparation of drugs for treating and reducing a fibrotic disease. The fibrotic disease is skin sclerosis, cardiac fibrosis, pulmonary fibrosis, hepatic fibrosis, pancreatic fibrosis, or renal fibrosis.

The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate and thiotungstate, and to the use of these agents in the prevention and treatment of inflammatory and/or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate wherein exemplary thiotungstates include mono-, di-, tri-. And tetrathiotungstate; these agents are administered to patients to prevent and/or treat inflammatory and/or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and/or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.

New therapeutic use of Polypodium extract. A new use of Polypodacea genus extracts is described for the treatment of fibrotic pathologies, such as, scleroderma, pulmonary fibrosis, atherosclerosis, bone marrow fibrosis, liver fibrosis, pancreatic fibrosis, kidney fibrosis, cardiac fibrosis, Dupuytrem's disease and, specially, Peyronie's disease; said fibrotic pathologies are produced by an extracellular matriz (ECM) overexpresion, and by a Transforming Growth Factor (TFG-β) overexpression. It is disclosed extracellular matriz inhibition in vitro; and penis tunica albuginea reduction and plaque redution in patients who suffer Peyronie's diseaseas after Polypodium extracts administration. In a preferred mode, Polypodium extracts are obtained from Polypodium leucotomos rhizomes and extraction with a polar solvent.

The invention relates to the fields of organic synthesis and medicinal chemistry, and relates to O-(1H-tetrazole) ethyl derivative of cleistanone, a preparation method thereof and an application thereof to preparing a drug for preventing or treating pancreatic fibrosis. The invention synthesizes a novel O-(1H-tetrazole) ethyl derivative of cleistanone and discloses a preparation method of the novel O-(1H-tetrazole) ethyl derivative. According to the pharmacology experiments, the O-(1H-tetrazole) ethyl derivative of cleistanone has the effect of preventing or treating pancreatic fibrosis, and has a value of developing a drug for preventing or treating pancreatic fibrosis.

The invention relates to application of total flavones of guava leaves in preparation of drugs for prevention and treatment of pancreatitis. The invention further provides a pharmaceutical compositionfor prevention and treatment of pancreatitis. The pharmaceutical composition comprises an effective therapeutic dose of total flavones of guava leaves as an active component and a pharmaceutically acceptable carrier. Animal experiments show that the total flavones of the guava leaves can inhibit the excessive proliferation of pancreatic stellate cells and alleviate the degree of pancreatic fibrosis by inhibiting the activation of the P2X7R-mediated NLRP3 inflammation signal pathway, have good effects on prevention and treatment of pancreatitis, have no toxic and side effects and can be used for preparing drugs for prevention and treatment of pancreatitis.

The invention relates to the fields of organic synthesis and medicinal chemistry, in particular to a composition, a preparation method, and application of the composition in preparation of medicine for preventing or treating pancreatic fibrosis. The invention discloses the composition and the preparation method thereof. A pharmacological experiment shows that the composition has the effect of preventing or treating pancreatic fibrosis, and has the value for developing medicine for preventing or treating pancreatic fibrosis.

The present invention belongs to the technical field of traditional Chinese medicines and discloses a traditional Chinese medicine formula for preventing pancreatic fibrosis. The traditional Chinese medicine formula comprises ground beeltles, leeches, white grubs, gadflies, semen armeniacae amarae, Chinese rhubarb, peach kernels, radix scutellariae, rhizoma rehmanniae, radix paeoniae alba, licorice, resina toxicodendri, radix salviae miltiorrhizae and cordyceps sinensis mycelia. The present invention also discloses a preparation method of the traditional Chinese medicine formula for preventingthe pancreatic fibrosis. Medicine weighing according to the formula, medicine drying, stirring and crushing, Chinese rhubarb decocting, mixing, pill manufacturing, etc. are conducted to prepare a finished product of water pills. The formula can lower blood sugar, can also treat low-grade inflammation of diabetes metabolism, simultaneously removes immune complexes and repairs islet cells, so as toprevent the pancreatic fibrosis. The preparation method prepares the formula into the water pills which are beneficial to absorption of active ingredients of the medicines and thus achieve an effectof rapid onset. The traditional Chinese medicine formula is free of toxic and side effects and suitable for use.

The invention discloses application of Akkermansia muciniphila in the aspect of treating chronic pancreatitis, and belongs to the application field of probiotics. The invention provides the application of an Akkermansia muciniphila BAA-835 strain in preparation of a product for treating chronic pancreatitis, and the strain can relieve pancreatic atrophy symptoms, acinus cell injury and inflammation infiltration, reduce release of proinflammatory cytokines and infiltration of macrophages, relieve pancreatic fibrosis degree in an active state or an inactive state, improve pancreatic fibrosis resistance and improve pancreatic fibrosis resistance. The compound can be used for preparing medicines, pharmaceutical compositions, functional foods and feeds for treating chronic pancreatitis, and has a wide application prospect.

The invention discloses application of a piperazinyl and dihydroxy ethylamino derivative composition of Atropurpuran to prevention and treatment of pancreatic fibrosis, namely, application of a composition of an O-(piperazine)ethyl derivative and an O-(ethylamino)ethyl derivative of the Atropurpuran to a medicament for treating or preventing the pancreatic fibrosis. The invention relates to the fields of organic synthesis and pharmaceutical chemistry, in particular to a composition of Atropurpuran derivatives, a preparation method of the composition and application of the composition to preparation of a medicament for preventing or treating the pancreatic fibrosis. The invention discloses a composition of Atropurpuran derivatives and a preparation method thereof. As proved by a pharmacology experiment, the composition of the Atropurpuran derivatives has the effect of preventing or treating the pancreatic fibrosis, and has a value of developing the medicament of preventing or treating the pancreatic fibrosis.

The invention relates to the field of organic synthesis and medicinal chemistry and in particular relates to a composition, a preparation method and an application of the composition to preparation of medicines for preventing or treating pancreatic fibrosis. The invention discloses the composition and the preparation method thereof. Pharmacological experiments show that the composition has the function of preventing or treating pancreatic fibrosis and has the value in developing the medicines for preventing or treating pancreatic fibrosis.

The invention relates to the field of organic synthesis and medicinal chemistry and in particular relates to a composition, a preparation method and an application of the composition to preparation of medicines for preventing or treating pancreatic fibrosis. The invention discloses the composition and the preparation method thereof. Pharmacological experiments show that the composition has the function of preventing or treating pancreatic fibrosis and has the value in developing the medicines for preventing or treating pancreatic fibrosis.

The invention relates to the fields of organic synthesis and medicinal chemistry, and in particular relates to a composition, a preparation method and application of the composition in preparing a drug for preventing or treating pancreatic fibrosis. The invention discloses a composition and a preparation method thereof. Based upon pharmacological experiments, the composition disclosed by the invention has an effect on preventing or treating the pancreatic fibrosis, so that the composition has the value of developing the drug for preventing or treating the pancreatic fibrosis.

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

The invention relates to the fields of organic synthesis and pharmaceutical chemistry, in particular to application of a composition of piperazine and imidazole based derivatives of Virosaine A in preparation of drugs for preventing or treating pancreatic fibrosis and discloses a composition and a preparation method thereof. Pharmacological experiments show that the composition has the effect of preventing or treating the pancreatic fibrosis and has the value of developing the drugs for preventing or treating the pancreatic fibrosis.